Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal...

Area of Science:

• Hematology
• Molecular Biology
• Oncology

Background:

• Nucleophosmin (NPM1) mutations in exon 12 are common in adult acute myeloid leukaemia (AML).
• NPM1 mutation A detection is a potential marker for minimal residual disease (MRD) monitoring in AML.
• Sensitive and specific assays are needed for routine NPM1 mutation A quantification.

Purpose of the Study:

• To establish a sensitive, specific, and reproducible real-time polymerase chain reaction (PCR) assay for quantifying NPM1 mutation A.
• To evaluate the clinical utility of this assay for monitoring MRD in AML patients with NPM1 mutations.
• To assess the correlation between NPM1 mutation A levels and therapeutic response.

Main Methods:

• Development of a calibrator-normalized relative quantification real-time PCR assay for NPM1 mutation A.
• Utilization of ABL1 as a reference housekeeping gene and OCI/AML3 cell line as a calibrator.
• Monitoring of NPM1 mutation A levels in 51 AML patients post-induction treatment.

Main Results:

• The developed assay demonstrated high sensitivity (10^-5) and specificity.
• NPM1 mutation A levels significantly reduced after induction therapy (median log(10) reduction of 2.48), correlating with treatment response.
• Clonal evolution was observed in 9.5% of patients, potentially limiting the long-term utility of NPM1 mutation A as a sole marker.

Conclusions:

• A sensitive and reproducible real-time PCR assay for NPM1 mutation A quantification was successfully established.
• The assay is valuable for routine MRD monitoring and assessing treatment response in NPM1-mutated AML.
• Clonal evolution necessitates careful interpretation of NPM1 mutation A levels in some AML cases.